improv sale growth temper
hilli margin setup promis
cl seri hit miss wide gross margin miss lower lift
colgat total relaunch present challeng strength hill return
growth china bright spot growth broad-bas region grow
except europ flat expect gross margin improv price take
hold mix improv though admittedli sore spot cl
time stabil key driven brand-build initi premium price
improv sale mix understand cloudi around cl share today given
mix print trim ep forecast continu believ number
initi management continu deliv improv recent month cl
alreadi address challeng key market like china russia india africa hill
mark
management maintain outlook net sale flat lsd ep msd
rais organ growth guid prior high end gm
guid slight declin prior expect expans in-lin organ growth
solid sign ep line bofaml estim penni street
benefit lower tax rate expect lend quarter shaki
management remain commit strategi premium total optic white
toothpast hill prescript diet focu natur invest behind brand
drive turnaround key market like slower north america still-tenu china
name larg stori long deliv margin expans
next quarter keep growth least line expect
reiter buy slightli trim estim po
reiter buy rate leav ep estim unchang
trim ep estimate reflect lower gross margin higher fx
pressur po still valu cl ep estimate in-
line target large-cap hpc think appropri cl take action
reinvest acquisit higher-growth categori cost save
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
person household fabric pet nutrit
brand includ ajax fab softsoap palmol
mennen speed stick hill pet nutrit
colgate-palmol product market
cl heavi exposur develop market
command market share oral care posit
compani well outpac peer earn
cash flow result see cl one
attract long-term growth stori larg
impact result recent see subsid
expect growth acceler next
view gross margin declin forefront today print even
manag acknowledg misstep ceo noel wallac got front
attribut impact sale mix ramp hill scienc diet follow
relaunch mix dilut outpac growth higher-margin prescript formula
margin dilut countri mix faster emerg market growth raw materi
pressur fx challeng appear well understood cl adam
plan turn around short order confid forecast return margin
expans next quarter though cogniz past misstep larg portion
problem come contract north america driven sub-optim
volum price higher manufactur cost effort acceler spend
digit capabl behind bigger brand provid lift along growth
skincar busi focu shift mix hill relaunch scienc
diet margin-accret prescript formula hill traction alreadi show
posit sign new display quarter sticki price that allow
addit round price start
though seem lost nois cl key prospect
hope innov premium portfolio provid sale
margin tailwind includ first-half roll-out natur innov global
roll-out optic white oral care broadli compani perform well across
geographi india africa grow despit tougher comp latam
benefit lap trucker strike brazil region remain nice
organ basi despit tenuou china perform asia improv post first
quarter growth year even china show promis on-line launch
net share persist problem china exacerb cl price
market distribut healthi readi innov move
tabl cl segment result summari comparison bofaml
updat guidanc also caus bristl better organ sale outlook lower
tax rate indian tax polici off-set gross margin lower full year basi given
outsiz impact third quarter miss leav fy ep outlook unchang
full detail
sale ep outlook maintain
tabl detail cl guidanc
flat lsd
flat lsd
high end
sale
sale
sale
depreci amort
ni non-controlling interest
ni non-controlling interest
mo end decemb
sale
sale
sale
depreci amort
ni attribut non-controlling inter
price object base forward price-to-earnings ep estim
premium large-cap stapl closer compani histor averag rel
market time cl gener best-in-class organ sale growth
demonstr abil manag difficult macro-economic/curr
environ recent result challeng organ sale improv
price ramp longer term see advantag countri categori exposur
risk downsid increas price competit stronger us macro
volatil particularli emerg market
olivia tong cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
helen troy
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
